Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular's Q1 Revenues Increase 62 Percent

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics reported after the close of the market on Monday that its first quarter revenues saw a 62 percent bump year over year in spite of a slowdown in product sales.

For the three months ended March 31, the firm reported $1.4 million in total revenues, compared to $865,232 in the year-ago period. While service revenues grew to $830,025 in Q1 2017 from $265,042 in Q1 2016, product revenues slid to $541,144 from $600,190.

"We are pleased with our momentum as we make progress toward increasing adoption of our products and services," HTG President and CEO TJ Johnson said in a statement. "Going forward, we will continue to focus on growing our partnerships with pharma and developing high-value diagnostic tests."

During the quarter, the firm reported a net loss of $5.8 million, or $.73 per share, compared to a net loss of $7.0 million, or $1.02 per share, a year ago.

HTG also said it shed 35 percent of its R&D costs year over year to $1.3 million from $2.0 million, while it cut its SG&A expenses 11 percent year over year to $4.2 million from $4.7 million.  

HTG finished the quarter with $2.8 million in cash and cash equivalents, and $2.6 million in short-term investments available for sale at fair value.

In February, the company appealed a delisting determination by Nasdaq after HTG's shares failed to regain compliance with a listing requirement calling for a minimum $10 million in stockholder equity.

Most recently, HTG and Spain's Instituto Valenciano de Oncologia reached a deal to develop and validate a breast cancer recurrence risk score, based on HTG's technology.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.